Valued Retirements Inc. Purchases New Shares in Edwards Lifesciences Co. (NYSE:EW)

Valued Retirements Inc. bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 2,894 shares of the medical research company’s stock, valued at approximately $214,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter worth $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $30,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter valued at about $32,000. Avior Wealth Management LLC raised its holdings in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares during the period. Finally, Roble Belko & Company Inc purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $46,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity

In other news, VP Daniel J. Lippis sold 400 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the sale, the vice president now directly owns 22,588 shares of the company’s stock, valued at approximately $1,569,414.24. This represents a 1.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 51,303 shares of company stock valued at $3,715,776. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of EW opened at $69.37 on Monday. The stock has a 50 day moving average price of $71.74 and a 200 day moving average price of $70.34. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $40.78 billion, a price-to-earnings ratio of 9.95, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on EW. Royal Bank of Canada restated an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Citigroup boosted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Truist Financial reiterated a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Finally, Piper Sandler boosted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.